MINNEAPOLIS/ST. PAUL (09/06/2022) — Published in JAMA, University of Minnesota Medical School researchers discovered the number of babies born in Minnesota with cytomegalovirus (CMV) decreased significantly during the COVID-19 pandemic. The study found that in the five-year period leading up to the pandemic, about one baby in every 200 births was born with CMV. Between August 2020 and December 2021, the number decreased to one baby in every 1,000 births.
“At last, something positive came out of the COVID-19 pandemic,” said Dr. Mark Schleiss, principal investigator of the study and a pediatric infectious disease specialist and professor in the U of M Medical School. “The hygienic precautions we all have engaged in during the pandemic — masking, hand-washing and infection prevention behaviors — were almost certainly responsible for the reduction in CMV transmission, which in turn protected mothers and newborns from the potentially devastating effects of the CMV virus.”
CMV is the most common virus that causes birth defects and disabilities in newborns.
Researchers concluded that the combination of strict hygienic precautions, stay-at-home practices and, most importantly, the closure of child care and group day care centers all resulted in reduced transmission of the CMV virus to children and their mothers during the pandemic. Women with toddlers in group day care are at risk for acquiring it from their child. If such infections occur during a subsequent pregnancy, the next child may be born with the infection and be at risk for developing disabilities, especially hearing loss.
The research team recommends further public awareness campaigns to increase knowledge and awareness of CMV. Dr. Schleiss was a part of the advocacy campaign that led to the Minnesota legislature’s passage of the Vivian Act in 2021. Led by Minnesota parents and doctors, the law made Minnesota the first state to start universal screening for congenital Cytomegalovirus in all newborn infants. The law aims to enhance knowledge and enable strategies for prevention of CMV infection.
This research was funded by the Centers for Disease Control and Prevention and the Minnesota Department of Health.
About the University of Minnesota Medical School
The University of Minnesota Medical School is at the forefront of learning and discovery, transforming medical care and educating the next generation of physicians. Our graduates and faculty produce high-impact biomedical research and advance the practice of medicine. We acknowledge that the U of M Medical School, both the Twin Cities campus and Duluth campus, is located on traditional, ancestral and contemporary lands of the Dakota and the Ojibwe, and scores of other Indigenous people, and we affirm our commitment to tribal communities and their sovereignty as we seek to improve and strengthen our relations with tribal nations. For more information about the U of M Medical School, please visit med.umn.edu.
Method of Research
Subject of Research
Assessment of Congenital Cytomegalovirus Prevalence Among Newborns in Minnesota During the COVID-19 Pandemic
Article Publication Date
Dr Schleiss reported receiving grants from the US Centers for Disease Control and Prevention (CDC), the National Institutes of Health, and the University of South Carolina Disability Research and Dissemination Center (DRDC) during the conduct of the study; and receiving personal fees from Moderna, Sanofi, GlaxoSmithKline, and Merck outside the submitted work. Ms Rosendahl and Mr McCann reported receiving grants from the CDC during the conduct of the study. No other disclosures were reported.
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.